R&D How innovative trial approaches are advancing rare disease r... Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.
R&D Novel study designs for rare diseases Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.
R&D External control arms and debunking real-world data myths For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies to patients faster, say COTA
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.